Related Experiment Video
Updated: Jul 6, 2026
09:56
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
A cyclic chimeric interferon-alpha2b peptide induces apoptosis in tumor cells
Viviana C Blank1, Clara Peña, Leonor P Roquin
1Instituto de Química y Fisicoquímica Biológicas (UBA-CONICET), Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina.
Cancer Biology & Therapy
|March 18, 2008
Summary
A novel chimeric cyclic peptide mimics Interferon alpha-2b (IFN-alpha2b) by inducing apoptosis, offering a potential new cancer treatment. This peptide activates caspases and alters Bcl-2 family proteins, similar to IFN-alpha2b, but without cell cycle arrest.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Interferons alpha (IFN-alpha) are used in cancer therapy but can face challenges like side effects and resistance.
- Developing effective IFN-alpha mimetic peptides is crucial for improving cancer treatment outcomes.
Purpose of the Study:
- To investigate the mechanism of growth inhibition by a synthesized chimeric cyclic peptide, a potential mimetic of IFN-alpha2b.
- To compare the effects of the chimeric peptide and native IFN-alpha2b on cell cycle progression and apoptosis in WISH cells.
Main Methods:
- Synthesis of a chimeric cyclic peptide designed to mimic IFN-alpha2b.
- Evaluation of the peptide's effect on WISH cell cycle progression.
- Assessment of apoptosis induction via caspase activation (caspases 8 and 9), Bcl-2 family protein expression, and cytochrome C release.
Main Results:
- The chimeric peptide induced apoptosis through both death receptor and mitochondrial pathways, involving caspase activation.
- Unlike IFN-alpha2b, the chimeric peptide did not induce cell cycle arrest.
- Both the peptide and IFN-alpha2b altered Bcl-2 family protein expression and led to cytochrome C release, confirming mitochondrial pathway involvement.
Conclusions:
- The chimeric cyclic peptide is a potent inducer of apoptosis.
- This peptide represents a promising therapeutic agent for treating certain malignancies, offering an alternative to traditional Interferon therapy.
Related Concept Videos
01:31The Intrinsic Apoptotic Pathway
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:17The Extrinsic Apoptotic Pathway
The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:27Cytotoxic T Cells-mediated Immune Response
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...